Plural Ring Hetero Atoms In The Bicyclo Ring System, Or Ring Nitrogen Is Shared By The Two Cyclos Of The Bicyclo Ring System Patents (Class 548/453)
-
Patent number: 7060843Abstract: Electroluminescent device comprising in this order (a) an anode (b) a hole transporting layer (c) a light-emitting layer (d) optionally an electron transporting layer and (e) a cathode and a light-emitting substance, wherein the light-emitting substance is a diketopyrrolopyrrole represented by formula I or formula III processes for the preparation of compounds I, its uses and compositions comprising the compounds I and/or III.Type: GrantFiled: September 8, 2000Date of Patent: June 13, 2006Assignee: Ciba Specialty Chemicals CorporationInventors: Junji Otani, Hiroshi Yamamoto, Norihisa Dan, Abul Iqbal, Robert Moretti
-
Patent number: 7045637Abstract: The invention provides novel pigment dispersants of the formula (I) in which Q is a radical of the formula (Ia) s is a number from 0.1 to 4.0 and n is a number from 0 to 2.0; and provides pigment preparations comprising an organic base pigment and a pigment dispersant of the formula (I).Type: GrantFiled: February 27, 2003Date of Patent: May 16, 2006Assignee: Clariant GmbHInventors: Joachim Weber, Felix Wendelin Grimm, Erwin Dietz
-
Patent number: 7045638Abstract: The invention provides novel pigment dispersants of the formula (I) in which is a radical of the formula (Ia) s is a number from 0.1 to 4.0 and n is a number from 0 to 2.0; and provides pigment preparations comprising an organic base pigment and a pigment dispersant of the formula (I).Type: GrantFiled: February 27, 2003Date of Patent: May 16, 2006Assignee: Clariant GmbHInventors: Joachim Weber, Felix Wendelin Grimm, Erwin Dietz
-
Patent number: 7041836Abstract: The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4-alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N—C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n— wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR3—. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: November 14, 2002Date of Patent: May 9, 2006Assignee: AstraZeneca UK LimitedInventors: Michael John Betts, Gareth Morse Davies, Michael Lingard Swain
-
Patent number: 7041695Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptorType: GrantFiled: July 30, 2004Date of Patent: May 9, 2006Assignee: WyethInventor: Derek Cecil Cole
-
Patent number: 7034150Abstract: A process for the preparation of a carbapenem antibacterial compound of the following formula (4) having a 1-alkylpyrrolidine structure or a salt thereof, a useful synthetic intermediate of the following formula (1) or a salt thereof, and a process for the preparation thereof: wherein R1 represents a C1–C3 alkyl group, R2 and R3 each independently represents a hydrogen atom or an organic residue or R2 and R3 together with the nitrogen atom they are attached to form a ring.Type: GrantFiled: May 14, 2003Date of Patent: April 25, 2006Assignee: Sankyo Company, LimitedInventors: Katsuhiko Fujimoto, Takashi Kasai
-
Patent number: 7001911Abstract: The invention pertains to fused cyclic compounds having the formula, wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7? or NR10, and M? is a bond or NR10, with the proviso that at least one of M or M? must be a bond; E is C?Z2, CR7CR7?, SO2, P?OR2, or P?OOR2; Z1 is O, S, NH, or NR6; Z2 is O, S, NH, or NR6; A1 is CR7 or N; A2 is CR7 or N; Y is J—J?—J? where J is (CR7R7?)n and n=0-3, J? is a bond or O, S, S?O, SO2, NH, NR6, C?O, OC?O, NR1C?O, CR7R7?, C?CR8R8?, R2P?O, OPOOR2, OPO2, OSO2, C?N, NHNH, NHNR6, NR6NH, N?N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J? is (CR7R7?)n and n=0-3; W is CR7R7?—CR7R7?, CR8?CR8?, CR7R7?—C?O, NR9—CR7R7?, N?CR8, N?N, NR9—NR9?, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; and O, R2, R6, R7, R7?, R8, R8?, R9, R9Type: GrantFiled: December 18, 2002Date of Patent: February 21, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, James Aaron Balog, Weifang Shan, Sören Giese, Lalgudi S. Harikrishnan
-
Patent number: 6992101Abstract: The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R?, R?, R??, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof in treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia.Type: GrantFiled: November 6, 2003Date of Patent: January 31, 2006Assignee: Pfizer, Inc.Inventors: Donald L. Bussolotti, Ronald B. Gammill, Jana Polivkova
-
Patent number: 6962894Abstract: A selectively herbicidal composition for controlling grasses and weeds in crops of useful plants, comprising a) a herbicidally effective amount of a compound of formula I or a salt or diastereoisomer of a compound of formula I, and b) an amount, which is effective for antagonism of the herbicide, of a compound of formula IIaType: GrantFiled: September 5, 2000Date of Patent: November 8, 2005Assignee: Syngenta Crop Protection, Inc.Inventor: Jutta Glock
-
Patent number: 6953801Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).Type: GrantFiled: May 21, 2002Date of Patent: October 11, 2005Assignee: Neurogen CorporationInventors: Alan Hutchison, Linda M. Gustavson, John M. Peterson, Dario Doller, Timothy M. Caldwell, Taeyoung Yoon, Wallace C. Pringle, Yiping Shen, Cheryl Steenstra
-
Patent number: 6924280Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: February 21, 2003Date of Patent: August 2, 2005Assignee: Pfizer Inc.Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
-
Patent number: 6911074Abstract: This invention relates to 1,4-diketopyrrolo[3,4c]-pyrrole pigments of the formula characterized by desirable color properties and novel visible absorbance spectra with a steep slope on the bathochromic side of the absorption maximum in the range of from 500 to 650 nm.Type: GrantFiled: July 8, 2004Date of Patent: June 28, 2005Assignee: CIBA Specialty Chemicals Corp.Inventors: Yves Grandidier, Albert Riegler, Klaus Ruf, Urs Schlatter
-
Patent number: 6908926Abstract: Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.Type: GrantFiled: April 12, 2000Date of Patent: June 21, 2005Assignee: Novo Nordisk A/SInventors: Florencio Zaragoza Dörwald, Knud Erik Andersen, Tine Krogh Jørgensen, Bernd Peschke, Birgitte Schjellerup Wulff, Ingrid Pettersson, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Müller, Bernd Krist
-
Patent number: 6894042Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which ?7 is known to be involved.Type: GrantFiled: February 13, 2003Date of Patent: May 17, 2005Assignee: Pharmacia & Upjohn CompanyInventors: Daniel Patrick Walker, David W. Piotrowski, Eric Jon Jacobsen, Brad A. Acker
-
Patent number: 6869971Abstract: UCS 1025 derivatives having antitumor activity or antibacterial activity which are represented by formula (I): wherein R1 represents hydrogen, lower alkyl, etc.; R2 represents hydrogen, or is combined with R3 to represent a bond, etc., or is combined with R4 to represent —O(C?O)—, etc.; R3 represents hydrogen, etc., or is combined with R2 to represent a bond, etc.; R4 represents hydrogen, etc., or is combined with R2 to represent —(C?O)O—, etc.; R5 represents hydrogen or is combined with R6 to represent a bond; R6 represents hydrogen, etc., or is combined with R5 to represent a bond; R7 represents hydrogen or is combined with R8 to represent ?O; R8 represents hydroxy or is combined with R7 to represent ?O; ---- represents a single bond or a double bond, and a represents a single bond (two carbon atoms to which a is bound are combined to form a single bond) or an oxygen atom, or pharmaceutically acceptable salts thereof.Type: GrantFiled: October 19, 2000Date of Patent: March 22, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tsutomu Akama, Akira Asai, Tsutomu Agatsuma, Shinji Nara, Yoshinori Yamashita, Tamio Mizukami, Shun-ichi Ikeda, Yutaka Saitoh, Yutaka Kanda
-
Publication number: 20040261662Abstract: The invention relates to a process for preparing pigments, which comprisesType: ApplicationFiled: July 8, 2004Publication date: December 30, 2004Inventors: Yves Grandidier, Albert Riegler, Klaus Ruf, Urs Schlatter, Takashi Deno
-
Publication number: 20040266816Abstract: A compound which is a carbamate of formula: 1Type: ApplicationFiled: July 10, 2002Publication date: December 30, 2004Inventors: Maria Antonia Buil Albero, Maria Dolors Fernandez Forner, Maria Prat Quinones
-
Publication number: 20040260072Abstract: This invention relates to new fluorescence dyes from the class of cyanine dyes, especially indotricarbocyanines with an absorption and fluorescence maximum in the spectral range of 700 to 900 nm, a thiol-specific reactive group, and three, preferably four, sulfonate groups, to an increase of water solubility as well as the production of dyes. This invention also relates to the conjugates of these dyes with biomolecules and uses thereof.Type: ApplicationFiled: January 23, 2004Publication date: December 23, 2004Inventors: Kai Licha, Christin Perlitz
-
Publication number: 20040259856Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: April 30, 2004Publication date: December 23, 2004Applicant: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Publication number: 20040259908Abstract: The present invention relates to a 2-phenyl-3-heteroarylpropionic acid derivative or a salt thereof, and also relates to a pharmaceutical agent and a VLA-4 and/or LPAM-1 antagonist each of which contains the same as an active ingredient.Type: ApplicationFiled: July 27, 2004Publication date: December 23, 2004Inventors: Satoru Ikegami, Yoichiro Hoshina
-
Publication number: 20040249162Abstract: The present invention relates to a process for the direct preparation of pyrrolo[3,4-c]pyrroles (DPPs) of the formula (I), pigment compositions containing them and their use for coloring high molecular weight organic materials, such as plastics and paints. The obtained DPPs of the formula I possess a higher colour strength, a higher chroma, a purer shade and a higher opacity versus corresponding commercially available DPPs.Type: ApplicationFiled: March 5, 2004Publication date: December 9, 2004Inventors: Vincent Ruffieux, Florence Modoux
-
Publication number: 20040242897Abstract: Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.Type: ApplicationFiled: December 10, 2003Publication date: December 2, 2004Inventors: Andrei P. Guzaev, Muthiah Manoharan
-
Publication number: 20040242629Abstract: A compound which is a carbamate of formula: 1Type: ApplicationFiled: March 31, 2003Publication date: December 2, 2004Inventors: Maria Antonia Buil Albero, Dolors Fernandez Forner, Maria Prat Quinones
-
Publication number: 20040235936Abstract: A process for preparing an anhydrous benzoate salt in crystalline form having the formula I: 1Type: ApplicationFiled: April 23, 2003Publication date: November 25, 2004Applicant: Pfizer Inc.Inventors: George Quallich, Michael J. Castaldi
-
Publication number: 20040236117Abstract: The invention relates to a process for the preparation of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-ylacetic acid, in which 5-benzyl-3,3-dimethyl-3,4-dihydro-2H-pyrrole is reacted with &ohgr;-bromo-4-chloroacetophenone with formation of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizine and the acetic acid group is introduced into the 5-position, 5-benzyl-3,3-dimethyl-3,4-dihydro-2H-pyrrole being obtained by hydrogenation of 2,2-dimethyl-4-oxo-5-phenylvaleronitrile or a ketal thereof. The invention also relates to processes for the preparation of intermediates occurring in the above process.Type: ApplicationFiled: June 4, 2004Publication date: November 25, 2004Inventors: Gerd Dannhardt, Thomas Kammermeier, Philipp Merckle, Hans-Gunter Striegel, Stefan Laufer
-
Patent number: 6821977Abstract: A compound of the formula whereon R1 is: R5 is: and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.Type: GrantFiled: February 19, 2003Date of Patent: November 23, 2004Assignee: Pfizer, Inc.Inventor: Ronald B. Gammill
-
Patent number: 6821964Abstract: Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein.Type: GrantFiled: March 6, 2002Date of Patent: November 23, 2004Assignee: Pfizer IncInventors: Roberto Colon-Cruz, Mary T. Didiuk, Erin M. Duffy, Ravi Garigipati, Wan F. Lau, Wayne S. McDonald
-
Publication number: 20040229846Abstract: Chiral ligands and metal complexes based on such chiral ligands useful in asymmetric catalysis are disclosed. The metal complexes according to the present invention are useful as catalysts in asymmetric reactions, such as, hydrogenation, hydride transfer, allylic alkylation, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, olefin metathesis, hydrocarboxylation, isomerization, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition; epoxidation, kinetic resolution and [m+n] cycloaddition. Processes for the preparation of the ligands are also described.Type: ApplicationFiled: May 28, 2004Publication date: November 18, 2004Applicant: The Penn State Research FoundationInventors: Xumu Zhang, Wenjun Tang
-
Publication number: 20040224976Abstract: The invention provides compounds of Formula I: 1Type: ApplicationFiled: June 15, 2004Publication date: November 11, 2004Inventors: Daniel Patrick Walker, David W. Piotrowski, Eric Jon Jacobsen, Brad A. Acker, Vincent E. Groppi
-
Publication number: 20040225111Abstract: The invention concerns vitronectin receptor antagonist compounds of formula (I): R1—Y-A-B-D-E-F-G wherein R1, Y, A, B, D, E, F, and G are as defined in the description, their physiologically acceptable salts and their prodrugs, methods for preparing compounds of formula (I), their use, in particular as medicine and pharmaceutical compositions containing them.Type: ApplicationFiled: November 4, 2002Publication date: November 11, 2004Inventors: Jacques Demassey, Jean-Francois Gourvest, Jean-Marie Ruxer, John Bernard Weston, Jean-Michel LeFrancois
-
Patent number: 6815440Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.Type: GrantFiled: March 3, 2003Date of Patent: November 9, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
-
Patent number: 6815439Abstract: Substituted aza-oxindole derivatives useful as cyclin dependent kinase II inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therapy.Type: GrantFiled: September 23, 2003Date of Patent: November 9, 2004Assignee: SmithKline Beecham CorporationInventors: Philip Anthony Harris, Lee Frederick Kuyper, Karen Elizabeth Lackey, James Marvin Veal
-
Publication number: 20040220173Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: April 6, 2004Publication date: November 4, 2004Applicant: Aventis Pharmaceutical Inc.Inventors: James A. Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M. Shutske, Joseph T. Strupczewski, Kenneth J. Bordeau, John G. Jurcak, Thaddeus R. Nieduzak, Sharon A. Jackson, Paul Angell, James P. Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Publication number: 20040220229Abstract: The invention provides compounds of formula (I) 1Type: ApplicationFiled: April 30, 2004Publication date: November 4, 2004Applicant: Pfizer IncInventors: Donald L. Bussolotti, Ronald B. Gammill
-
Publication number: 20040220251Abstract: The synthesis and study of biological activity of a series of new molecules with potential antimicrobial activity are described. The molecules are bicyclic carbohydrates, based on furanose sugars. Their antimicrobial activity against viruses is demonstrated, next to cytostatic effects. Significantly, a high and selective activity against Cytomegalovirus was observed.Type: ApplicationFiled: January 20, 2004Publication date: November 4, 2004Inventors: Benedikt Sas, Johan Van hemel, Jan Vandenkerckhove, Eric Peys, Johan Van der Eycken, Steven Van Hoof
-
Publication number: 20040209876Abstract: The present application describes modulators of CCR3 of formula (I):Type: ApplicationFiled: May 11, 2004Publication date: October 21, 2004Inventors: John V. Duncia, Joseph B. Santella, Daniel S. Gardner, Dean A. Wacker
-
Publication number: 20040186160Abstract: The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.Type: ApplicationFiled: December 12, 2003Publication date: September 23, 2004Applicant: SUGEN, Inc.Inventors: Peng Cho Tang, Yi Xia, Rachael Hawtin
-
Publication number: 20040180235Abstract: The present invention relates to fluorescent diketopyrrolopyrroles (“DPPs”) of Formula (I), wherein A1 and A2 independently from each other stand for (II) wherein R1, R2 and R5 to R11 are as defined in claim 1, a process for their preparation and their use for the preparation of inks, colorants, pigmented plastics for coating, non-impact-printing material, color filters, cosmetics, or for the preparation of polymeric ink particles, toners, dye lasers and electroluminescent devices. The fluorescent diketopyrrolopyrroles (“DPPs”) of Formula (I) exhibit a high lightfastness, a high heat stability, especially in plastics. A luminescent device comprising a DPP compound of Formula (I) is high in the efficiency of electrical energy utilisation, high in luminance and high in colour purity.Type: ApplicationFiled: December 22, 2003Publication date: September 16, 2004Inventors: Hiroshi Yamamoto, Norihisa Dan, Olof Wallquist
-
Publication number: 20040171847Abstract: The present invention relates to a process for the preparation of diketopyrrolopyrroles of the formula (I), wherein A1, A2, A3 and A4 are as defined in the description of the present invention, to new diketopyrrolopyrroles of the general formula I obtainable by the process, and the use of the new diketopyrrolopyrroles of the general formula I for the preparation of inks, colorants, pigmented plastics for coatings, non-impact-printing material, color filters, cosmetics, polymeric ink particles, toners, dye lasers and electroluminescent devices, or as fluorescent markers for immunoassays and fluorescent tracers for leak detection of fluids. Furthermore the present invention relates to diketopyrrolopyrrole analogues of the general formula (II), wherein A1, A2 and A3 are defined in the description of the present invention, which are intermediates in the process for the preparation of diketopyrrolopyrroles of the formula I and can be used as crystal growth regulators.Type: ApplicationFiled: February 4, 2004Publication date: September 2, 2004Inventors: Colin Morton, David Macdonald Smith, Vincent Ruffieux
-
Patent number: 6780887Abstract: The present invention is related to a compound of formula (I), salts and pro-drugs of the compound (I) and methods for treating and/or preventing partial or total ischemia, methods for treating and/or preventing pathologies associated with ischemia or with mitochondrial deficiencies.Type: GrantFiled: July 30, 2002Date of Patent: August 24, 2004Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Carine Michiels, Martine Redon, Jose Remacle
-
Publication number: 20040157907Abstract: The present invention provides compounds of formula (I) 1Type: ApplicationFiled: November 6, 2003Publication date: August 12, 2004Applicant: Pfizer IncInventors: Donald L. Bussolotti, Ronald B. Gammill, Jana Polivkova
-
Publication number: 20040152905Abstract: Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and chemically modified oligonucleotide analogs, are provided. In addition, methods for functionalization of a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.Type: ApplicationFiled: February 2, 2004Publication date: August 5, 2004Inventors: Andrei P. Guzaev, Muthiah Manoharan
-
Publication number: 20040152897Abstract: Disclosed are methods of preparing substituted indolizines represented by the following formula: 1Type: ApplicationFiled: September 11, 2003Publication date: August 5, 2004Applicant: Synta Pharmaceuticals Corp.Inventors: Lijun Sun, Keizo Koya, Zhi-Qiang Xia, Teresa Przewloka, Shijie Zhang, Mitsunori Ono
-
Patent number: 6770664Abstract: Bicyclic heterocyclic substituted phenyl oxazolidinone compounds of the formula: wherein Y is a radical of Formulae II or III: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.Type: GrantFiled: June 9, 2003Date of Patent: August 3, 2004Inventors: Steven D. Paget, Dennis J. Hlasta
-
Publication number: 20040138436Abstract: The present invention relates to colorant of the general formula, wherein A, B and B′, m and m′ and n and n′ are as defined in the description. The colorants can be used for the pigmenting of porous materials and in injekt printing and, in the case of pigmenting, are converted to the insoluble pigment form. In the pigmenting of porous materials, for example in the pigmenting of wood or anodised aluminium in the pores, the colorants yield very good penetration and fastness to light and, in injekt printing, yield very good water-resistance.Type: ApplicationFiled: October 16, 2003Publication date: July 15, 2004Inventors: Hans-Thomas Schacht, Gilbert Moegle
-
Publication number: 20040138475Abstract: The present invention relates to the host-guest solid solutions formed from a mixture of 1,4-diketo-3,6-bis(4-chlorophenyl)pyrrolo[3,4-c]pyrrole (para-dichloro DPP) and 1,4-diketo-3,6-bis(4-methylphenyl)pyrrolo[3,4-c]pyrrole (para-dimethyl DPP). The mixture contains between 30-80 mol percent of para-dimethyl DPP and 70-20 mol percent of para-dichloro DPP. The present invention further relates to the preparation of the solid solutions, and to the use of the solid solutions and binary solid compounds as pigments.Type: ApplicationFiled: October 20, 2003Publication date: July 15, 2004Inventors: Zhimin Hao, Shivakumar Basalingappa Hendi
-
Publication number: 20040138250Abstract: Compounds of general formula (I) or general formula (II) wherein R1, P1, P2, Q, Y, (X)o, (W)n, (V)m, Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds.Type: ApplicationFiled: January 8, 2004Publication date: July 15, 2004Inventor: Martin Quibell
-
Publication number: 20040132797Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer.Type: ApplicationFiled: February 10, 2004Publication date: July 8, 2004Inventors: Arnold S Lippa, Joseph W Epstein
-
Publication number: 20040127530Abstract: The present invention provides certain [3.1.0] bicyclic oxazolidinone derivatives of Formulea I and II, described herein, or pharmaceutically acceptable salts or prodrugs thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.Type: ApplicationFiled: October 2, 2003Publication date: July 1, 2004Inventors: Mikhail Fedor Gordeev, Adam Renslo, Dinesh Vinoobhai Patel
-
Patent number: 6756378Abstract: Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.Type: GrantFiled: December 28, 2001Date of Patent: June 29, 2004Assignees: Pharmacopeia Drug Discovery, Inc., Daiichi Pharmaceutical Co., Ltd.Inventors: John J. Baldwin, Edward McDonald, Kevin Joseph Moriarty, Christopher Ronald Sarko, Nobuo Machinaga, Atsushi Nakayama, Jun Chiba, Shin Iimura, Yoshiyuki Yoneda